Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration date of ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.

Earnings Call Insights: Blueprint Medicines Corporation (BPMC) Q1 2025. Management View. CEO Kate Haviland highlighted a 61% year-over-year increase in AYVAKIT revenue, crediting growing patient ...

Blueprint Medicines will receive $775 million in upfront payments, including a cash payment of $675 million and an equity investment by Roche of $100 million in Blueprint Medicines' common stock ...

Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Equities researchers at Zacks Research boosted their Q4 2026 earnings per share estimates for Blueprint Medicines in a research note ...

Blueprint Medicines (BPMC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham maintained a Buy rating on the stock and ...

In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $116.35, a high estimate of $168.00, and a low estimate of $75.00.

JMP Securities analyst Reni Benjamin has reiterated their bullish stance on BPMC stock, giving a Buy rating on June 4. Reni Benjamin has given his Buy rating due to a combination of factors ...

Paris: Sanofi has announced the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a ...

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation ( ...